{"id":5267,"date":"2022-03-31T11:32:24","date_gmt":"2022-03-31T09:32:24","guid":{"rendered":"https:\/\/pharmavalue.it\/?p=5267"},"modified":"2022-04-22T18:52:19","modified_gmt":"2022-04-22T16:52:19","slug":"recovery-of-unused-resources-of-the-national-aifa-fund-5","status":"publish","type":"post","link":"https:\/\/pharmavalue.it\/en\/recovery-of-unused-resources-of-the-national-aifa-fund-5\/","title":{"rendered":"Recovery of unused resources of the AIFA National Fund 5%"},"content":{"rendered":"<p>The 5% fund for rare diseases, which allows access to medicines that are not yet marketed in Italy and which represent a hope of cure for patients suffering from rare and serious diseases, is fed by the marketing expenses of pharmaceutical companies (congresses, medical-scientific information, etc.), expenses which, due to the pandemic, have been greatly reduced, making 'only' 10.5 million available in 2021 compared to, for example, 20 million in 2010.<\/p>\n<p>Recall that in November 2021, the agency's evaluation activity was temporarily suspended precisely to cope with the increase in applications and the decrease in the fund.<\/p>\n<p>The determination published on 30\/03\/22 in the OJ serves to recover unused resources in relation to treatments that were never started or stopped early, in respect of which reimbursement or only partial reimbursement was never requested.<\/p>\n<h3>What does the recently issued 5% fund access authorisation measure say<\/h3>\n<p><strong>For fund authorisations authorised up to 31\/12\/2019<\/strong> and for which reimbursement (full or partial) has not yet been requested \u279c AUTHORISATION REVOKED<\/p>\n<p><strong>For fund authorisations authorised between 1\/1\/2020 and 30\/09\/2021<\/strong> \u279c may request partial or full reimbursement by 31\/05\/2022<\/p>\n<p><strong>For fund authorisations authorised as from 1\/10\/2021<\/strong> \u279c must request reimbursement within 60 days of treatment and no later than 8 months after authorisation<\/p>\n<p><a href=\"https:\/\/pharmavalue.it\/en\/new-criteria-for-accessing-fund-5-of-law-326-2003\/\">To read again about the New Criteria for Access to the 5% Fund of Law 326\/2003 please consult our article<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Il Fondo 5% per le malattie rare, che consente l\u2019accesso a medicinali non ancora commercializzati in Italia e che rappresentano una speranza di cura per pazienti affetti da malattie rare e gravi, \u00e8 alimentato dalle spese di marketing delle aziende farmaceutiche (congressi, informazione medico scientifica, ecc.), spese che, a causa della pandemia, si sono fortemente [&hellip;]<\/p>\n","protected":false},"author":314,"featured_media":5269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"9","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":""},"categories":[9],"tags":[46,59,60],"class_list":["post-5267","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-appunti","tag-aifa","tag-early-access","tag-farmaci-orfani"],"_links":{"self":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/5267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/users\/314"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/comments?post=5267"}],"version-history":[{"count":0,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/5267\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media\/5269"}],"wp:attachment":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media?parent=5267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/categories?post=5267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/tags?post=5267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}